Chat with MASLD AI
Hi, I am MASLD AI.
Suggested Questions :
MASLD AI 06:48 AM
November 2025
Learn the fundamentals of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in this educational session featuring Edith Johannes, NP, a liver specialist at UCLA Health with over 17 years of experience in hepatology and liver transplantation. Supported by the GHAPP MASLD Community Network and Madrigal Pharmaceuticals, this session explores the new terminology and diagnostic criteria for MASLD—formerly known as NAFLD and NASH—and explains why these changes matter for both clinicians and patients. Viewers will gain a clear understanding of how to evaluate patients presenting with hepatic steatosis, distinguish MASLD from alcohol- or drug-induced liver injury, and apply key diagnostic tools such as FIB-4, ELF testing, and elastography to assess fibrosis progression. Johannes also discusses the clinical importance of ruling out overlapping conditions, recognizing metabolic risk factors, and identifying patients at risk for fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Whether you’re new to hepatology or seeking a concise refresher, this talk provides a practical framework for diagnosing and managing MASLD in primary and specialty care.
Related Webcast
Webcast: MASLD Pharmacotherapy With Ellie Gonyeau
September 2025
In this practical, clinician-focused talk, Ellie Gonyeau, NP, walks through a streamlined pharmacotherapy framework for MASLD/MASH—anchored on three pillars: obesity management, cardiometabolic risk reduction (T2D, hypertension, dyslipidemia), and liver-directed therapy. She reviews where GLP-1 receptor agonists fit (weight loss, glycemic control, peri-procedure considerations), summarizes evidence and patient selection for high-dose vitamin E and pioglitazone, and explains the role of resmetirom—the first FDA-approved therapy for non-cirrhotic MASH with F2–F3 fibrosis—its liver-selective THR-β mechanism, pivotal trial outcomes, common AEs, and drug-interaction/ statin considerations. You’ll also learn how to monitor and restage using non-invasive tests (FibroScan kPa/CAP, ELF, labs), set measurable lifestyle goals, and navigate real-world questions around coverage, testing cadence, and treatment duration—so you can confidently tailor therapy and improve outcomes for patients across the MASLD/MASH spectrum.
Watch Now
Webcast: MASLD vs MetALD With Oyin Penny
October 2025
In this educational session, Oyin Penny, FNP, from Premier Gastroenterology of Kansas City, discusses the overlap between MASLD and MetALD, highlighting how metabolic risk factors and alcohol intake accelerate liver injury and fibrosis. Presented through the GHAPP MASLD Community Network and supported by Madrigal Pharmaceuticals, this talk uses a real-world case study to explain diagnostic tools like FibroScan, CAP score, and PEth testing, along with clinical criteria for distinguishing MASLD, MetALD, and ALD. Key management strategies include Mediterranean diet, weight loss, alcohol abstinence, and monitoring for advanced fibrosis and HCC risk.
Watch Now
Live From GHAPP National: Abnormal Liver Imaging: What's Next?
November 2025
In this high-yield session, HoChong Gilles, NP from the Central Virginia VA Healthcare System, guides viewers through a practical approach to abnormal liver imaging and the challenge of incidental liver lesions. She reviews how to differentiate cystic versus solid liver lesions, outline key risk factors, and interpret enhancement patterns on ultrasound, CT, and MRI to distinguish benign findings—such as simple cysts, hemangiomas, FNH, and hepatic adenomas—from malignant lesions including hepatocellular carcinoma (HCC) and metastatic disease. Designed for APPs and clinicians who frequently encounter unexpected lesions on imaging, this concise overview provides clear strategies for knowing when to reassure, when to monitor, and when to escalate evaluation or referral.
Watch Now
Webcast: MASLD Basics With Scott Springer
August 2025
Welcome to the GHAPP MASLD Community Network, where Scott Springer, PA-C, from Erie County Medical Center in Buffalo, NY, provides a comprehensive overview of the evolving landscape of steatotic liver disease. Sponsored by Madrigal Pharmaceuticals, this session breaks down the recent nomenclature shift from NAFLD/NASH to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and MASH (Metabolic Dysfunction-Associated Steatohepatitis). Scott explores how overlapping etiologies like alcohol-associated liver disease (ALD) and the emerging classification of MetALD better reflect real-world patient populations. Learn about key diagnostic strategies—including the use of FIB-4, ELF score, and transient elastography—to assess fibrosis risk and guide referral to hepatology care. With a clinical case study, Scott highlights the importance of accurate staging, ruling out alternative etiologies, and understanding progression rates in high-risk patients. This session is a must-watch for GI and hepatology APPs looking to stay updated on guidelines, non-invasive diagnostics, and best practices for managing MASLD/MASH in primary and specialty settings.
Watch Now
Webcast: MASLD vs MetALD Webcast
October 2025
In this educational presentation, Emily Przybyl, PA-C, from Erie County Medical Center, explores the overlap between Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and MetALD, emphasizing how metabolic risk factors and alcohol intake accelerate liver injury and fibrosis. Presented through the GHAPP MASLD Community Network and supported by Madrigal Pharmaceuticals, this session uses a real-world case study to illustrate diagnostic evaluation, non-invasive testing (FibroScan, CAP score, FIB-4), and the role of PEth testing in objectively assessing alcohol use. Emily also highlights the importance of dietary changes, Mediterranean-style nutrition, weight reduction, and alcohol abstinence in preventing progression to cirrhosis and improving patient outcomes.
Watch Now
Webcast: Comparing F3 and F4 Fibrosis With Kristina Tuesday Werner
October 2025
Tuesday Werner, NP, explains why accurately identifying F3 vs F4 fibrosis is critical in patients with MASLD/MASH. Using real patient case comparisons, she highlights how non-invasive tests like FIB-4, FibroScan, and ELF help determine disease severity, guide treatment, and reduce the need for biopsy. Tuesday reviews how care strategies differ—F3 patients focus on aggressive metabolic control and fibrosis monitoring, while F4 (cirrhosis) requires HCC surveillance, closer specialist follow-up, and potential transplant evaluation.
Watch Now
Webcast: Non-Invasive Testing With Lindsay Pratt
July 2025
In this educational session from the GHAPP MASLD/MASH Community Network, Lindsay Pratt, PA-C from the University of Colorado, guides viewers through the practical application of non-invasive testing (NITs) for assessing fibrosis in patients with MASLD (Metabolic dysfunction-associated steatotic liver disease). Using a real-world case study, she highlights how to interpret FIB-4, ELF score, vibration-controlled transient elastography (VCTE/FibroScan®), and MR elastography (MRE) to stratify patients by risk and guide next steps in management. Lindsay explains the strengths and limitations of each NIT, how lifestyle modifications and cardiometabolic risk factors play a role in disease progression, and how tools like the AGA Clinical Care Pathway can be applied in day-to-day practice. This session is ideal for hepatologists, GI providers, APPs, and primary care professionals working to improve outcomes in patients with fatty liver disease—without relying on liver biopsy.
Watch Now
Webcast: MASLD Pharmacotherapy With HoChong Gilles
September 2025
In this MASLD Community Network webcast, HoChong Gilles, DNP from the Central Virginia VA Health Care System, provides an in-depth review of pharmacotherapy for MASLD and MASH. The session highlights how management historically focused on lifestyle modification, weight loss, and cardiometabolic risk reduction, and how the treatment landscape shifted in March 2024 with the FDA approval of resmetirom (Rezdiffra)—the first therapy specifically indicated for non-cirrhotic MASH with stage 2–3 fibrosis. HoChong also reviews the evidence and practical use of GLP-1 receptor agonists like semaglutide, including data from the ESSENCE trial, as well as the limited but notable roles of vitamin E and pioglitazone. Key discussion points include drug mechanisms, clinical trial outcomes, real-world safety considerations, drug–drug interactions, and monitoring strategies for patients on therapy. This presentation underscores the importance of integrating lifestyle change with emerging pharmacologic options to improve liver outcomes in patients with MASLD and MASH.
Watch Now
Webcast: Comparing F3 and F4 Fibrosis With Valerie Shin
September 2025
In this interactive case discussion, Valerie Shin, NP, from UCLA Health’s hepatology team, walks through how to compare F3 and F4 fibrosis in patients with metabolic dysfunction–associated steatohepatitis (MASH). Presented as part of the GHAPP MASLD Community Network series sponsored by Madrigal, this session uses real-world patient data to explore how non-invasive testing (NITs) like FibroScan, FIB-4, and ELF testing help stage liver fibrosis and guide treatment decisions. Valerie highlights the importance of accurate staging for prognosis, monitoring, and management—whether identifying patients with advanced fibrosis (F3) who may benefit from resmetirom (Rezdiffra), or recognizing progression to cirrhosis (F4) that requires enhanced surveillance and multidisciplinary care. This video also emphasizes practical strategies for lifestyle modification, metabolic risk factor control, and liver cancer screening. Whether you are a hepatology specialist, primary care provider, or advanced practice provider (APP), this case comparison offers valuable clinical insights into diagnosing and managing MASLD/MASH.
Watch Now
Webcast: MASLD vs MetALD With Erin Tanner
November 2025
Join Erin Tanner, PA-C for a practical overview of MASLD (metabolic-associated steatotic liver disease) and MetALD, the overlap between metabolic dysfunction and alcohol-related liver injury. Through a real-world case, Erin explains how to interpret FibroScan (kPa/CAP) results, use PEth testing to objectively measure alcohol intake, and recognize how alcohol accelerates fibrosis progression. She reviews risk factors like hypertension, hyperlipidemia, and elevated triglycerides, emphasizing lifestyle interventions, Mediterranean diet, weight loss, and alcohol abstinence to prevent decompensation and liver cancer.
Watch Now